Please enable JavaScript to continue using this application.

Compare $ANIK vs $FATE | Chartloom

Compare

$ANIK vs $FATE

Anika Therapeutics Inc · Fate Therapeutics Inc

ANIK

Anika Therapeutics Inc

FATE

Fate Therapeutics Inc

Compare $ANIK vs $FATE

Comparing Anika Therapeutics Inc and Fate Therapeutics Inc

ANIKAnika Therapeutics Inc

FATEFate Therapeutics Inc

ANIKAnika Therapeutics Inc

Market cap

$262M

P/E (TTM)

—

Forward P/E (NTM)

57.30x

Forward P/S (NTM)

2.09x

Rev growth (TTM)

-2.5%

YTD performance

109.4%

52W performance

111.9%

FCF yield

0.2%

FATEFate Therapeutics Inc

Market cap

$254M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

54.34x

Rev growth (TTM)

-23.4%

YTD performance

120.2%

52W performance

44.4%

FCF yield

-41.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ANIK

FATE

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

FATE

Fate Therapeutics Inc

Market Cap

ANIK$262M

FATE$254M

Enterprise Value

ANIK$224M

FATE$234M

Price

ANIK$19.58

FATE$2.18

P/E Ratio

ANIKN/A

FATEN/A

P/S Ratio

ANIK2.17x

FATE39.15x

EV/Sales

ANIK1.85x

FATE35.98x

EV/EBITDA

ANIK84.97x

FATE0.00x

P/B Ratio

ANIK1.86x

FATE1.81x

P/FCF Ratio

ANIK466.16x

FATEN/A

EV/FCF

ANIK397.81x

FATE-2.21x

PEG Ratio

ANIKN/A

FATEN/A

Forward P/E (NTM)

ANIK57.30x

FATEN/A

Forward P/S (NTM)

ANIK2.09x

FATE54.34x

Revenue (TTM)

ANIK$121M

FATE$6M

Revenue Growth (YoY)

ANIK-2.5%

FATE-23.4%

Forward Rev Growth

ANIK5.2%

FATE-17.6%

Gross Margin (TTM)

ANIK62.2%

FATE0.0%

Operating Margin (TTM)

ANIK0.0%

FATE0.0%

EBITDA Margin (TTM)

ANIK2.2%

FATE-1873.4%

Net Margin (TTM)

ANIK-3.1%

FATE-1941.1%

FCF Margin (TTM)

ANIK0.5%

FATE-1627.8%

Net Income (TTM)

ANIK$-4M

FATE$-126M

FCF (TTM)

ANIK$562K

FATE$-106M

EPS (TTM)

ANIK-$0.28

FATE-$1.05

ROE (TTM)

ANIK-270.0%

FATE-6508.0%

ROA (TTM)

ANIK-204.0%

FATE-4173.0%

ROIC (TTM)

ANIK-270.0%

FATE-6174.0%

Cash

ANIK$38M

FATE$32M

Debt

ANIK$0

FATE$12M

Net Cash/Debt

ANIK$38M

FATE$21M

Current Ratio (TTM)

ANIK4.48x

FATE4.85x

Quick Ratio (TTM)

ANIK3.05x

FATE4.74x

Debt/Equity (TTM)

ANIK0.00x

FATE0.08x

Debt/Assets (TTM)

ANIK0.0%

FATE0.0%

Interest Coverage (TTM)

ANIKN/A

FATEN/A

Net Debt/EBITDA (TTM)

ANIK0.00x

FATE0.00x

Beta

ANIK0.23

FATE2.67

52W Performance

ANIK111.9%

FATE44.4%

YTD Performance

ANIK109.4%

FATE120.2%

% from 52W High

ANIK-14.4%

FATE-32.5%

% from 52W Low

ANIK125.8%

FATE129.5%

Asset Turnover (TTM)

ANIK0.65x

FATE0.02x

FCF Yield (TTM)

ANIK0.2%

FATE-41.6%

Earnings Yield (TTM)

ANIK-1.4%

FATE-49.6%

Dividend Yield (TTM)

ANIKN/A

FATEN/A

Rule of 40

ANIK-2.0

FATE-1,651.1

EV/GP/RG

ANIK0.81

FATEN/A

Ticker research

View ANIK research View FATE research

Metric	ANIK Anika Therapeutics Inc	FATE Fate Therapeutics Inc
Market & Valuation
Market Cap	$262M	$254M
Enterprise Value	$224M	$234M
Price	$19.58	$2.18
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	39.15x
EV/Sales	1.85x	35.98x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	1.81x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-2.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	54.34x
Revenue & Growth
Revenue (TTM)	$121M	$6M
Revenue Growth (YoY)	-2.5%	-23.4%
Forward Rev Growth	5.2%	-17.6%
Profitability
Gross Margin (TTM)	62.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	-1873.4%
Net Margin (TTM)	-3.1%	-1941.1%
FCF Margin (TTM)	0.5%	-1627.8%
Net Income (TTM)	$-4M	$-126M
FCF (TTM)	$562K	$-106M
EPS (TTM)	-$0.28	-$1.05
ROE (TTM)	-270.0%	-6508.0%
ROA (TTM)	-204.0%	-4173.0%
ROIC (TTM)	-270.0%	-6174.0%
Financial Health
Cash	$38M	$32M
Debt	$0	$12M
Net Cash/Debt	$38M	$21M
Current Ratio (TTM)	4.48x	4.85x
Quick Ratio (TTM)	3.05x	4.74x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	2.67
52W Performance	111.9%	44.4%
YTD Performance	109.4%	120.2%
% from 52W High	-14.4%	-32.5%
% from 52W Low	125.8%	129.5%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.02x
FCF Yield (TTM)	0.2%	-41.6%
Earnings Yield (TTM)	-1.4%	-49.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	-1,651.1
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View FATE research

Valuation

P/S Ratio

ANIK

2.17x

FATE

39.15x

EV/FCF

FATE

-2.21x

ANIK

397.81x

Growth & revenue

Revenue Growth TTM

ANIK

-2.5%

FATE

-23.4%

Forward Revenue Growth

ANIK

5.2%

FATE

-17.6%

Profitability & performance

Gross Margin

ANIK

62.2%

FATE

0.0%

ROE

ANIK

-270.0%

FATE

-6508.0%

FCF Yield %

ANIK

0.2%

FATE

-41.6%

52-Week Performance

ANIK

111.9%

FATE

44.4%

Detailed metrics comparison

ANIK

Anika Therapeutics Inc

FATE

Fate Therapeutics Inc

Market Cap

ANIK$262M

FATE$254M

Enterprise Value

ANIK$224M

FATE$234M

Price

ANIK$19.58

FATE$2.18

P/E Ratio

ANIKN/A

FATEN/A

P/S Ratio

ANIK2.17x

FATE39.15x

EV/Sales

ANIK1.85x

FATE35.98x

EV/EBITDA

ANIK84.97x

FATE0.00x

P/B Ratio

ANIK1.86x

FATE1.81x

P/FCF Ratio

ANIK466.16x

FATEN/A

EV/FCF

ANIK397.81x

FATE-2.21x

PEG Ratio

ANIKN/A

FATEN/A

Forward P/E (NTM)

ANIK57.30x

FATEN/A

Forward P/S (NTM)

ANIK2.09x

FATE54.34x

Revenue (TTM)

ANIK$121M

FATE$6M

Revenue Growth (YoY)

ANIK-2.5%

FATE-23.4%

Forward Rev Growth

ANIK5.2%

FATE-17.6%

Gross Margin (TTM)

ANIK62.2%

FATE0.0%

Operating Margin (TTM)

ANIK0.0%

FATE0.0%

EBITDA Margin (TTM)

ANIK2.2%

FATE-1873.4%

Net Margin (TTM)

ANIK-3.1%

FATE-1941.1%

FCF Margin (TTM)

ANIK0.5%

FATE-1627.8%

Net Income (TTM)

ANIK$-4M

FATE$-126M

FCF (TTM)

ANIK$562K

FATE$-106M

EPS (TTM)

ANIK-$0.28

FATE-$1.05

ROE (TTM)

ANIK-270.0%

FATE-6508.0%

ROA (TTM)

ANIK-204.0%

FATE-4173.0%

ROIC (TTM)

ANIK-270.0%

FATE-6174.0%

Cash

ANIK$38M

FATE$32M

Debt

ANIK$0

FATE$12M

Net Cash/Debt

ANIK$38M

FATE$21M

Current Ratio (TTM)

ANIK4.48x

FATE4.85x

Quick Ratio (TTM)

ANIK3.05x

FATE4.74x

Debt/Equity (TTM)

ANIK0.00x

FATE0.08x

Debt/Assets (TTM)

ANIK0.0%

FATE0.0%

Interest Coverage (TTM)

ANIKN/A

FATEN/A

Net Debt/EBITDA (TTM)

ANIK0.00x

FATE0.00x

Beta

ANIK0.23

FATE2.67

52W Performance

ANIK111.9%

FATE44.4%

YTD Performance

ANIK109.4%

FATE120.2%

% from 52W High

ANIK-14.4%

FATE-32.5%

% from 52W Low

ANIK125.8%

FATE129.5%

Asset Turnover (TTM)

ANIK0.65x

FATE0.02x

FCF Yield (TTM)

ANIK0.2%

FATE-41.6%

Earnings Yield (TTM)

ANIK-1.4%

FATE-49.6%

Dividend Yield (TTM)

ANIKN/A

FATEN/A

Rule of 40

ANIK-2.0

FATE-1,651.1

EV/GP/RG

ANIK0.81

FATEN/A

Ticker research

View ANIK research View FATE research

Metric	ANIK Anika Therapeutics Inc	FATE Fate Therapeutics Inc
Market & Valuation
Market Cap	$262M	$254M
Enterprise Value	$224M	$234M
Price	$19.58	$2.18
P/E Ratio	N/A	N/A
P/S Ratio	2.17x	39.15x
EV/Sales	1.85x	35.98x
EV/EBITDA	84.97x	0.00x
P/B Ratio	1.86x	1.81x
P/FCF Ratio	466.16x	N/A
EV/FCF	397.81x	-2.21x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	57.30x	N/A
Forward P/S (NTM)	2.09x	54.34x
Revenue & Growth
Revenue (TTM)	$121M	$6M
Revenue Growth (YoY)	-2.5%	-23.4%
Forward Rev Growth	5.2%	-17.6%
Profitability
Gross Margin (TTM)	62.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	2.2%	-1873.4%
Net Margin (TTM)	-3.1%	-1941.1%
FCF Margin (TTM)	0.5%	-1627.8%
Net Income (TTM)	$-4M	$-126M
FCF (TTM)	$562K	$-106M
EPS (TTM)	-$0.28	-$1.05
ROE (TTM)	-270.0%	-6508.0%
ROA (TTM)	-204.0%	-4173.0%
ROIC (TTM)	-270.0%	-6174.0%
Financial Health
Cash	$38M	$32M
Debt	$0	$12M
Net Cash/Debt	$38M	$21M
Current Ratio (TTM)	4.48x	4.85x
Quick Ratio (TTM)	3.05x	4.74x
Debt/Equity (TTM)	0.00x	0.08x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.23	2.67
52W Performance	111.9%	44.4%
YTD Performance	109.4%	120.2%
% from 52W High	-14.4%	-32.5%
% from 52W Low	125.8%	129.5%
Efficiency & Yields
Asset Turnover (TTM)	0.65x	0.02x
FCF Yield (TTM)	0.2%	-41.6%
Earnings Yield (TTM)	-1.4%	-49.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-2.0	-1,651.1
EV/GP/RG	0.81	N/A
Ticker research	View ANIK research	View FATE research